Netherlands · Delayed Price · Currency is EUR IMCD N.V. Earnings Call Transcripts
Fiscal Year 2025
-
2025 saw strong early growth but was followed by challenging quarters due to macroeconomic and currency headwinds, leading to softer demand and lower margins. Acquisitions and strategic initiatives supported stability, while management remains cautiously optimistic for 2026.
-
Gross profit and revenue grew year-over-year despite macroeconomic and tariff headwinds, with acquisitions contributing to top-line growth. Margin pressure stemmed from mix and M&A, while digital initiatives and cost controls are being intensified. Leverage remains stable, and management is confident in long-term prospects.
-
Gross profit and EBITDA grew in H1 2025, but Q2 saw demand soften amid global uncertainty and currency headwinds. Working capital and net debt increased due to higher inventories and acquisitions, while pharmaceutical and food & nutrition segments remained resilient.
-
Q1 2025 delivered double-digit profit and EBITA growth despite global uncertainty and tariffs. Americas and Asia Pacific drove strong results, while EMEA lagged due to inflation. CEO transition completed, with a robust M&A pipeline and no strategic disruptions.
Fiscal Year 2024
-
Gross profit and EBITDA grew after a weak Q1, with strong M&A activity and a healthy order book. Margins were pressured by inflation, but leverage and cash flow remain strong. Outlook is positive but cautious due to ongoing geopolitical and market volatility.
-
Revenue and EBITDA grew in the first nine months, driven by acquisitions and organic gains, with all regions showing Q3 improvement. Market volatility and limited visibility persist, but digital and sustainability investments continue, and leverage remains well below covenants.
-
Revenue for H1 2024 was EUR 2.385 billion with operating EBITDA of EUR 270 million, reflecting a 2% decrease year-over-year due to a weak Q1 but strong Q2 recovery. Eleven acquisitions supported growth, while market volatility and limited visibility persist.